<?xml version="1.0" encoding="UTF-8"?>
<ref id="R89">
 <label>89.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>O’Brien</surname>
    <given-names>SM</given-names>
   </name>
   <name>
    <surname>Byrd</surname>
    <given-names>JC</given-names>
   </name>
   <name>
    <surname>Hillmen</surname>
    <given-names>P</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis</article-title>. 
  <source>
   <italic toggle="yes">Am J Hematol.</italic>
  </source>
  <year>2019</year>;
  <volume>94</volume>:
  <fpage>554</fpage>–
  <lpage>562</lpage>.
  <pub-id pub-id-type="pmid">30767298</pub-id>
 </mixed-citation>
</ref>
